BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Strategia Holdings, JS InnoPharm team up for drug development

August 28, 2018 | News

Through this partnership, both companies will leverage their comprehensive knowledge in the global development of multiple therapeutics.



Strategia Holdings, LLC has announced a strategic partnership alliance with JS InnoPharm (Shanghai), Ltd. to facilitate global drug development. Through this partnership, both companies will leverage their comprehensive knowledge, broad expertise, drug candidates, and networks in the global development of multiple therapeutics.

The Strategia Holdings group currently consists of three biopharmaceutical companies- Spirita Oncology, LLC, Mirata BioPharma, LLC, and Strategia Pharmaceuticals, LLC. All three organizations will work closely together with JS InnoPharm under the Strategic Partnership Alliance.

“JS InnoPharm is keen on collaborating with Strategia to establish long-term commitments to accelerate global drug development with us,” said Dr. Jintao Zhang, CEO of JS InnoPharm. “We believe in the power of China and the US coming together and crafting solutions to enhance efficiencies and achieve faster drug development timelines with higher success rates. This partnership allows the organizations to work closely together in a collaborative effort to reach those goals.”